Addex Therapeutics focuses on the discovery and development of an emerging class of oral small molecule drugs that can be exquisitely selective for their intended target and confer significant therapeutic advantages over conventional “orthosteric” small molecule or biological drugs. ADDXF’s … Continue reading →

Alliqua is a biomedical company focused on the development, manufacturing and marketing of its own proprietary products based on the company’s existing technology portfolio. ALQA currently markets its own proprietary brands of wound dressings: SilverSeal® Hydrogel, an antimicrobial dressing; and … Continue reading →

Cyclacel Pharmaceuticals is a biopharmaceutical company developing oral therapies for the treatment of cancer and other serious diseases. The company has three product candidates are currently in clinical development: Sapacitabine (CYC682) for the treatment of acute myeloid leukemia (AML) in … Continue reading →

MetaStat is a life science company operating through its subsidiary MetaStat BioMedical to develop and commercialize proprietary clinical diagnostic tests that predict the probability of blood borne systemic metastasis of cancer; and therapeutics to prevent systemic metastasis. Its products include … Continue reading →

ImmunoVaccine is a clinical-stage vaccine development company focused on advancing its patented DepoVax™ vaccine adjuvanting platform and product candidates for cancer therapy, infectious diseases and animal health. The company’s pipeline also includes a broad range of infectious diseases programs including … Continue reading →

Genmab is a biotech company engaged in the development of human antibody therapeutics for the treatment of cancer in Denmark and internationally. The company has one product on the market, ofatumumab, and is developing a pipeline of fully human antibody … Continue reading →

Echo Therapeutics is a transdermal medical device company specializing in skin permeation technology. The company is developing its Prelude® SkinPrep System as a platform technology to allow for significantly enhanced and painless skin permeation that will enable needle-free drug delivery … Continue reading →

Ohr Pharmaceutical is engaged in the development of novel therapeutics for the treatment of serious and unmet medical needs. The company’s lead compounds include OHR/AVR 118 for the treatment of cancer cachexia, and Squalamine eye drops for the treatment of … Continue reading →